Allarity Therapeutics Inc
Change company Symbol lookup
Select an option...
ALLR Allarity Therapeutics Inc
DARE Dare Bioscience Inc
REXR-C Rexford Industrial Realty Inc
AQNA Algonquin Power & Utilities Corp
NAOV Nanovibronix Inc
IOT Samsara Inc
GSIT GSI Technology Inc
GME GameStop Corp
CMBM Cambium Networks Corp
S SentinelOne Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Allarity Therapeutics, Inc. is a clinical-stage, precision medicine pharmaceutical company. It is advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its clinical program includes three anti-cancer assets in mid-stage clinical development and one anti-cancer asset in early-stage clinical development. Its programs and partnerships leverage its Drug Response Predictor technology to refine patient selection and improve clinical outcomes. It is focused on clinical development of three programs: dovitinib in combination with stenoparib for the second-line or later treatment of metastatic ovarian cancer; stenoparib as a monotherapy for ovarian cancer, and IXEMPRA as a monotherapy for metastatic breast cancer. Its dovitinib is a selective inhibitor of several classes of tyrosine kinases, including FGFR and VEGFR. Its IXEMPRA is a selective microtubule inhibitor, which has been shown to interfere with cancer cell division, to cell death.

Postmarket

Last Trade: Delayed
$0.2651

Change Since Close Change Since Close Postmarket extended hours change is based on the last price at the end of the regular hours period. Premarket extended hours change is based on the day's regular session close.: -0.0021 (-0.79%)

Bid: --

Ask: --

B/A Size: --

Market Hours

Closing Price: $0.2672

Day's Change: 0.011 (4.29%)

Bid close: --

Ask close: --

B/A Size: --

Day's High: 0.2799

Day's Low: 0.2575

Volume (Light) Volume: 969,976 10-day average volume: 1,974,410: 969,976

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

The risk of loss in trading futures can be substantial. Clients must consider all relevant risk factors, including their own personal financial situation, before trading. Margin and level 2 options approval or higher is required. Not all account owners will qualify.

Dividends are converted to USD using the current rate of exchange at the end of the business day on the day the dividend went EX. Earnings are converted to USD using the current rate of exchange at the end of the business day on the day earnings were announced.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.

Postmarket

Change Since Close

Market Hours